Find a study
Browse recruiting studies near you — free to check, always your choice.
125 studies
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
- COPD (chronic lung disease)
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Testing two doses of a medicine versus placebo for COPD symptoms
📍 Research Site · Birmingham, AL · +39 more US sites · Get directions →
This Phase IIb dose-ranging study will evaluate the efficacy and safety of 2 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive pulmonary disease.
- COPD (chronic lung disease)
Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency
Testing how a genetic change in alpha-1 antitrypsin affects immune and lung responses to a pneumonia
📍 University of Alabama at Birmingham · Birmingham, AL · Get directions →
The goal of this study is to learn whether patients who have a genetic mutation in the genes that cause alpha 1 antitrypsin deficiency also have genetic variation in nearby genes that can increase risk for reduced immune function and respiratory infections. To investigate this hypothesis, we will compare immune responses to the 20-valent pneumococcal conjugate vaccine (PCV20, Pfizer) between participants who have one abnormal copy of the SERPINA1 gene and either no COPD exacerbations, vs those with 2 or more COPD exacerbations in the past year.
- COPD (chronic lung disease)
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
Testing a shot versus placebo for COPD symptoms in adults with high eosinophils
📍 University of Alabama at Birmingham- Site Number : 8400003 · Birmingham, AL · +39 more US sites · Get directions →
This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive) with inadequately controlled Chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. Participation to the study consists of 3 periods: * Screening period of up to 4 weeks * Randomized intervention period of approximately 48 weeks * Follow-up period: Approximately 8 weeks The study duration will be up to 60 weeks.
- Multiple sclerosis (MS)
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Testing remibrutinib in people with relapsing multiple sclerosis who switch from ocrelizumab versus
📍 Perseverance Research Center · Scottsdale, AZ · +39 more US sites · Get directions →
The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).
- Multiple sclerosis (MS)
Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)
Testing the safety and effects on disease and immune cells of one dose of YTB323 in people with
📍 Novartis Investigative Site · Darlinghurst, New South Wales · Get directions →
This is an open-label, multi-center, non-confirmatory study to assess the safety, disease progression, and cellular kinetics following YTB323 administration to 28 participants with non-active Progressive Multiple Sclerosis (PMS). The study design utilizes an ascending single dose design consisting of 3 sentinel cohorts followed by an expansion cohort.
- Multiple sclerosis (MS)
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Testing a modified ublituximab treatment for relapsing multiple sclerosis
📍 TG Therapeutics Investigational Trial Site · Birmingham, AL · +34 more US sites · Get directions →
The primary purpose of this phase 3b study is to assess the efficacy of a modified regimen of ublituximab in participants with relapsing multiple sclerosis (RMS) as measured by T1 Gadolinium (Gd)-enhancing lesions in Part A; PK in Part B along with efficacy of ublituximab as measured by T1 Gd-enhancing lesions in participants who had a suboptimal experience on prior anti-CD20 therapy in Part C. The study consists of 3 parts: Part A is single-armed and open-label, Part B is randomized, double-blind, placebo-controlled, and Part C is single-armed and open-label.
- COPD (chronic lung disease)
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Testing the long-term safety of astegolimab in people with COPD
📍 UAB Lung Health Center · Birmingham, AL · +39 more US sites · Get directions →
The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.
- Multiple sclerosis (MS)
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
Testing safety of a new immune cell therapy in adults with multiple sclerosis
📍 Research Site · Tucson, AZ · +8 more US sites · Get directions →
This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with Multiple Sclerosis.
- Multiple sclerosis (MS)
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
Testing safety of a twice-yearly medicine for early relapsing MS
📍 Northwestern Memorial Hospital · Chicago, IL · Get directions →
In this prospective, open-label, single-arm, single-institution trial, the investigators will accomplish the following two aims: 1. study the safety and tolerability of Ublituximab (Briumvi) twice annually in participants with early MS over a treatment observation period of \~12 months.
- Rheumatoid arthritis
Oral Versus Intramuscular Steroid Use to Control Rheumatoid Arthritis Flares
Comparing pills versus shots of steroids to control rheumatoid arthritis flares
📍 Sunnybrook Health Sciences Centre · Toronto, Ontario · Get directions →
People living with rheumatoid arthritis (RA) often experience flares-periods where their symptoms suddenly get worse. These flares can cause significant pain, make it harder to move and do daily activities, and lower overall quality of life.
- COPD (chronic lung disease)
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
Testing whether tezepelumab is safe and works for adults with COPD
📍 Research Site · Foley, AL · +39 more US sites · Get directions →
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
- Multiple sclerosis (MS)
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Testing the safety and effects of KITE-363 in people with multiple sclerosis
📍 Stanford Neuroscience Health Center · Palo Alto, CA · +3 more US sites · Get directions →
This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with relapsed/refractory autoimmune neurologic diseases.
- Multiple sclerosis (MS)
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
Testing whether combining a walking medication with physical therapy improves mobility in people
📍 MGH Institute of Health Professions · Boston, MA · Get directions →
The goal of this clinical trial is to evaluate if combining a medication that can help improve walking in people with multiple sclerosis (MS) with a physical therapy program is better for improving walking than either treatment alone. The main questions this study will answer are: * Does combining dalfampridine with physical therapy improve mobility more than physical therapy without concurrent dalfampridine?
- Multiple sclerosis (MS)
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
Testing a CD19 CAR-T cell treatment for progressive multiple sclerosis
📍 Stanford Multiple Sclerosis Center · Palo Alto, CA · Get directions →
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis
- Rheumatoid arthritis
Dynamic Treatment Regiments for Glucocorticoid Tapering
Studying how people with rheumatoid arthritis respond to tapering steroid medicine
📍 VA Ann Arbor Healthcare System, Ann Arbor, MI · Ann Arbor, MI · +1 more US site · Get directions →
The purpose of this clinical trial is to better understand how people with rheumatoid arthritis (RA) respond to gradual dose reduction, or "tapering", of steroid medications like prednisone. Some people with RA have symptoms when steroid dose is reduced, while others don't.
- COPD (chronic lung disease)Asthma
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
Testing whether positive airway pressure helps a lung medicine (NAC) reach mucus plugs in asthma or
📍 UCSF Airway Clinical Research Center · San Francisco, CA · Get directions →
The goal of this clinical trial is to determine if positive pressure during inspiration will improve penetration of aerosolized N-Acetylcysteine (NAC) into airway mucus plugs in the lungs of patients with asthma or Chronic Obstructive Pulmonary Disease (COPD). The main questions it aims to answer are: * Does delivery of aerosolized NAC with positive inspiratory pressure have a greater effect on mucus plug burden in the lungs than delivery of NAC without positive pressure.
- COPD (chronic lung disease)
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
Testing a medicine added to standard care for moderate to severe COPD
📍 GSK Investigational Site · Sheffield, AL · +39 more US sites · Get directions →
Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.
- Multiple sclerosis (MS)
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Testing a drug called BMS-986368 for muscle stiffness in multiple sclerosis
📍 Alabama Neurology Associates · Birmingham, AL · +14 more US sites · Get directions →
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity
- COPD (chronic lung disease)
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
Testing two doses of a daily medicine versus placebo in people with COPD over 52 weeks
📍 DM Clinical Research - Phoenix · Phoenix, AZ · +11 more US sites · Get directions →
This is a Phase 2 study of the efficacy, safety, tolerability and pharmacokinetics of two doses of EXPD-101 in participants with COPD. Study participants will be randomized to receive either study drug or placebo administered once daily for 52 weeks.
- Multiple sclerosis (MS)
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Testing a drug called orelabrutinib versus placebo in people with PPMS
📍 Arizona Neuroscience Research, LLC · Pheonix, AZ · +12 more US sites · Get directions →
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with PPMS.
- Lupus (SLE)Rheumatoid arthritis
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
Testing a CD19-targeted CAR T cell treatment in people with severe lupus or rheumatoid arthritis
📍 University of Colorado Anschutz Medical Campus · Aurora, CO · +30 more US sites · Get directions →
The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases (Breakfree-1).
- Multiple sclerosis (MS)
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
Checking if two under-the-skin versions of ocrelizumab match in the body in people with multiple
📍 Profound Research, LLC · Carlsbad, CA · +8 more US sites · Get directions →
The main purpose of this study is to assess the bioequivalence of ocrelizumab SC test formulation to the marketed ocrelizumab SC reference formulation in participants with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). The study consists of 2 phases: a controlled phase, where participants in each group will receive one dose of test or reference formulation and a continuation phase, where all participants in both groups will receive ocrelizumab SC test formulation.
- Multiple sclerosis (MS)
Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques
Testing whether corticosteroids change inflammation in acute MS lesions
📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →
Background: Multiple sclerosis (MS) affects the brain, spinal cord, and optic nerves. MS lesions can appear on the MRI (magnetic resonance imaging) scans in many ways.
- Multiple sclerosis (MS)
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Comparing stem cell transplant vs best available treatment for relapsing multiple sclerosis
📍 Stanford Multiple Sclerosis Center · Palo Alto, CA · +21 more US sites · Get directions →
This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio.
- Rheumatoid arthritis
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Testing safety and effects of cord blood immune cells plus rituximab for relapsing rheumatoid
📍 Artiva Investigational Site Tuscaloosa · Tuscaloosa, AL · +30 more US sites · Get directions →
A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically modified allogeneic NK cell, in combination with rituximab.
- Rheumatoid arthritis
A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)
Testing different doses of ELV001 for rheumatoid arthritis symptoms
📍 Arizona Arthritis & Rheumatology Associates · Gilbert, AZ · +21 more US sites · Get directions →
This is a Phase 2 randomized, double-blind, placebo-controlled study with a total duration of 32 weeks from Screening to End-of-Study (EOS) Visit. Approximately 180 participants are planned to be enrolled.
- Rheumatoid arthritis
Advanced Therapeutics in Rheumatoid Arthritis (RA)
Tracking how long two rheumatoid arthritis treatments are kept in adults
📍 Rheumatology Clinic, St. Joseph's Health Care · London, Ontario · Get directions →
This study will evaluate the retention rates of two advanced therapies, Tumour Necrosis Factor (TNF) and Janus kinase inhibitor (JAK) in the treatment of adults with Rheumatoid Arthritis (RA) over a two year period. It will also examine the ability to embed a clinical trial in a clinical situation using an electronic medical record (EMR).
- Multiple sclerosis (MS)
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
Testing solriamfetol to treat tiredness from multiple sclerosis
📍 Johns Hopkins University · Baltimore, MD · Get directions →
Fatigue is a prevalent and disabling symptom in Multiple Sclerosis (MS), affecting up to 90% of patients. Current treatments, including off-label prescriptions of wake-promoting agents, have shown limited effectiveness.
- Rheumatoid arthritis
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
Testing how safe and tolerable an immune-cell treatment is for rheumatoid arthritis
📍 Nkarta Investigational Site · Orange, CA · +14 more US sites · Get directions →
This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.
- Multiple sclerosis (MS)
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Testing orelabrutinib versus placebo for people with non-active secondary progressive multiple
📍 Arizona Neuroscience Research, LLC · Phoenix, AZ · +12 more US sites · Get directions →
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS.
- COPD (chronic lung disease)
Multi-Center Clean Air Randomized Controlled Trial in COPD
Testing whether using an air cleaner improves COPD symptoms and quality of life
📍 University of Alabama, Lung Health Center · Birmingham, AL · +10 more US sites · Get directions →
This is a multi-center randomized, sham-controlled clinical trial to determine the effectiveness of an air cleaner intervention aimed at improving indoor air quality on reducing COPD exacerbation risk and improving quality of life, functional status, rescue medication use.
- Multiple sclerosis (MS)
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
Testing how a new medicine given through a vein or under the skin is handled and tolerated in people
📍 Stanford University Medical Center · Stanford, CA · +4 more US sites · Get directions →
The primary purpose of the study is to evaluate the safety and tolerability of a single-ascending intravenous (IV) dose (Part 1), a single-ascending subcutaneous (SC) dose (Part 2), and multiple ascending SC doses (Part 3) of RO7121932 in participants with multiple sclerosis (MS).
- Multiple sclerosis (MS)
Home Based Infusions for Ocrelizumab
Testing the safety and effectiveness of home infusions of ocrelizumab for multiple sclerosis
📍 Amerita · Centennial, CO · Get directions →
The goal is to assess the safety and effectiveness of home ocrelizumab infusion.
- High blood pressureCOPD (chronic lung disease)
Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
Testing tadalafil to see if it improves shortness of breath in COPD with high blood pressure in the
📍 Rocky Mountain Regional VA Medical Center, Aurora, CO · Aurora, CO · +4 more US sites · Get directions →
The investigators will study whether the drug tadalafil improves shortness of breath in 126 Veterans with Chronic Obstructive Pulmonary Disease (COPD) and high blood pressure in the lungs. The investigators will also assess whether tadalafil improves quality of life, home daily physical activity, exercise endurance, the frequency of acute flares of COPD, blood pressure in the lungs, and lung function.
- Multiple sclerosis (MS)
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
Testing ozanimod versus fingolimod in children with multiple sclerosis
📍 Local Institution - 0114 · Loma Linda, CA · +11 more US sites · Get directions →
The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).
- Multiple sclerosis (MS)
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
Testing whether TRX319 is safe for people with progressive multiple sclerosis
📍 University of Kansas Medical Center · Kansas City, KS · +1 more US site · Get directions →
The goal of this clinical trial is to treat male and female participants with two types of Multiple Sclerosis (MS) called primary progressive or secondary progressive MS. The main questions the trial aims to answer are the following: * Is TRX319 safe when administered to patients with progressive forms of MS?
- Rheumatoid arthritis
Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
Testing how a single dose works and whether it is safe in people with rheumatoid arthritis
📍 Mayo Clinic · Scottsdale, AZ · +8 more US sites · Get directions →
This study will test the safety and effects of SBT777101 when given as a single dose to subjects with rheumatoid arthritis. It is the first study of this treatment being done in humans.
- Rheumatoid arthritis
Study of GS-0151 in Participants With Rheumatoid Arthritis
Testing a study drug in people with rheumatoid arthritis to assess safety
📍 Pinnacle Research Group, LLC · Anniston, AL · +17 more US sites · Get directions →
The goal of this clinical study is to learn more about the study drug GS-0151. The study is done to find how safe, well-tolerated the drug is.
- COPD (chronic lung disease)
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Testing a skin injection to treat long-term COPD in adults with high eosinophils
📍 Chandler Clinical Research Trials- Site Number : 8400025 · Chandler, AZ · +39 more US sites · Get directions →
This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive) with inadequately controlled Chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. Participation to the study consists of 3 periods: * Screening period of up to 4 weeks * Randomized intervention period of approximately 48 weeks * Follow-up period: Approximately 8 weeks The study duration will be up to 60 weeks.
- Multiple sclerosis (MS)
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
Testing a new drug’s safety and effects in people with multiple sclerosis
📍 Local Institution - 0011 · Birmingham, AL · +16 more US sites · Get directions →
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or Refractory Myasthenia Gravis (MG).
- Multiple sclerosis (MS)
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Testing a medicine to reduce brain and eye tissue loss in people with multiple sclerosis
📍 Johns Hopkins University · Baltimore, MD · +1 more US site · Get directions →
The goal of this clinical trial is to evaluate if the study drug will reduce brain and retinal atrophy by reducing inflammation and subsequently slowing neurodegeneration in people with Multiple Sclerosis. The main outcome for the trial is change in normalized brain parenchymal volume (nBPV), measured by magnetic resonance imaging (MRI).
- Rheumatoid arthritis
"Effect of Vitamin E (α-Tocopherol) on Clinical Activity and Inflammation in Rheumatoid Arthritis"
Testing whether vitamin E lowers inflammation and symptoms in rheumatoid arthritis
📍 Civil Hospital of Guadalajara · Guadalajara, Jalisco · Get directions →
The objective of this clinical trial is to determine whether α-tocopherol (vitamin E) supplementation decreases inflammation and clinical activity in patients with rheumatoid arthritis (RA).The main questions to be answered are: * Is supplementation with vitamin E (α-tocopherol) for one month associated with decreased clinical activity and inflammation in patients with RA? Researchers will compare α-tocopherol with a placebo (a look-alike substance containing no active ingredient) to see if α-tocopherol effectively reduces inflammation and clinical activity in patients with rheumatoid arthritis.
- Dementia / Alzheimer'sMultiple sclerosis (MS)
Exploring the Utility of [18F]3F4AP for Demyelination Imaging
Testing how an imaging tracer works in people with memory loss and multiple sclerosis
📍 Yale University PET Center · New Haven, CT · Get directions →
The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).
- Multiple sclerosis (MS)
Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis
Testing whether special MRI using hyperpolarized carbon can predict how relapsing-remitting MS
📍 Byers Hall · San Francisco, CA · Get directions →
The main purpose of this study is to assess whether hyperpolarized carbon imaging in relapsing remitting multiple sclerosis (MS) patients can be used to predict response to anti-CD20 disease modifying therapy. Study procedures will include magnetic resonance imaging (MRI) assessments with a hyperpolarized pyruvate sequence, clinical assessment as well as blood markers of disease progression.
- COPD (chronic lung disease)
Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)
Testing an add-on treatment for adults having a COPD flare with type 2 inflammation
📍 University of Alabama at Birmingham Lung Health Center · Birmingham, AL · +21 more US sites · Get directions →
This is a Phase 2, multicenter study in adult participants with an acute COPD exacerbation and type 2 inflammation
- COPD (chronic lung disease)
A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP)
Testing different doses of BBT002 in people with COPD and in healthy adults
📍 Equity Medical Bowling Green · Bowling Green, KY · +2 more US sites · Get directions →
Randomized study of single and multiple doses of BBT002 in healthy volunteers and in adult patients with chronic obstructive pulmonary disease (COPD) or chronic rhinosinusitis with nasal polyps (CRSwNP).
- Rheumatoid arthritis
Imaging of Lymphatic Vessels in People With Rheumatoid Arthritis (RA)
Testing ways to see lymph vessels in people with rheumatoid arthritis
📍 University of Rochester · Rochester, NY · Get directions →
Lymphatic transport was previously examined by these investigators using Near InfraRed Indocyanine Green fluorescence imaging (NIR-ICG) of the upper extremities. They established reliable and reproducible methodologies in RA patients.
- COPD (chronic lung disease)
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
Testing an add-on medicine to treat moderate to severe COPD with type 2 inflammation
📍 GSK Investigational Site · Loxahatchee Groves, FL · +3 more US sites · Get directions →
Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.
- Multiple sclerosis (MS)
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Testing how well and how safely remibrutinib works in secondary progressive multiple sclerosis
📍 Alabama Neurology Associates PC · Birmingham, AL · +32 more US sites · Get directions →
The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis (SPMS)
- Rheumatoid arthritis
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
Testing targeted treatments for people with moderate to severe rheumatoid arthritis
📍 Sun Valley Arthritis Center /ID# 278331 · Peoria, AZ · +39 more US sites · Get directions →
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies for the treatment of moderately to severely active Rheumatoid Arthritis (RA).
- Rheumatoid arthritis
A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis
Testing how a treatment called LY4213663 is tolerated and side effects in people with rheumatoid
📍 Pinnacle Research Group, LLC · Anniston, AL · +8 more US sites · Get directions →
The purpose of this study is to evaluate how well LY4213663 is tolerated and what side effects may occur in healthy participants and participants with rheumatoid arthritis (RA). The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm).
- Multiple sclerosis (MS)💵 May compensate
Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod
Testing whether ozanimod is safe and works as a step-down treatment for stable multiple sclerosis
📍 University of Colorado Anschutz Medical Campus · Aurora, CO · +2 more US sites · Get directions →
A multi-center pilot study to evaluate safety and efficacy of ozanimod as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.
- COPD (chronic lung disease)
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Comparing inhalers to see how triple breathing medicine affects heart and lung outcomes in COPD
📍 Research Site · Athens, AL · +39 more US sites · Get directions →
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
- Rheumatoid arthritis
A Study of AZD0120 in Autoimmune Diseases
Testing safety of a gene-cell treatment in adults with hard-to-treat rheumatoid arthritis
📍 Research Site · Tucson, AZ · +7 more US sites · Get directions →
This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), or difficult-to-treat rheumatoid arthritis (D2T RA).
- COPD (chronic lung disease)
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD
Testing different doses of two inhaled medicines for COPD symptoms
📍 SEC Clinical Research, LLC · Dothan, AL · +39 more US sites · Get directions →
This study will assess the safety and efficacy of fixed dose combinations of ensifentrine with two different glycopyrrolate dose levels compared to placebo and to the individual components of the fixed dose combinations, each administered twice a day via standard jet nebulizer, in adult subjects with chronic obstructive pulmonary disease (COPD).
- Multiple sclerosis (MS)
Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis
Testing whether switching from ocrelizumab to ublituximab helps MS symptoms that return
📍 Johns Hopkins University · Baltimore, MD · Get directions →
The proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon.
- COPD (chronic lung disease)💵 May compensate
Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure
Comparing inhaled triple versus double medicines for COPD lung airways after wood smoke exposure
📍 Insituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas" · Mexico City, Tlalpan · Get directions →
This phase IV randomized controlled clinical trial intend to compare the effect of three close standard inhaled triple therapies and one close standard inhaled double therapy on the small airway in patients with Chronic Obstructive Pulmonary Disease (COPD-B) and chronic bronchitis without obstruction (BCNO) exposed to wood smoke. The treatment phase duration is of 3 months.
- COPD (chronic lung disease)
Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators
Comparing nebulizer and inhaler treatments for COPD symptoms
📍 The University of Tennessee Graduate School of Medicine · Knoxville, TN · Get directions →
The purpose of this study is to compare the effectiveness of inhaled bronchodilators delivered via nebulizers vs. dry powder inhalers (DPIs) in symptomatic participants with Chronic Obstructive Pulmonary Disease (COPD) who have airflow obstruction (FEV1/FVC ≤ 70%) and show significant air trapping (RV ≥ 120% of predicted).
- Multiple sclerosis (MS)
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Testing metformin alone or with other treatment in older people with multiple sclerosis
📍 UBMD Neurolgy · Buffalo, NY · Get directions →
The goal of the study is to learn about treating older people with multiple sclerosis (MS) with metformin. Metformin may be used as a single therapy or as an add-on therapy.
- Lupus (SLE)Rheumatoid arthritisCrohn's / ulcerative colitis (IBD)
COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
Testing COVID-19 booster and flu vaccine schedules in people with lupus, rheumatoid arthritis, or
📍 Maisonneuve -Rosemont Installation · Montreal, Quebec · Get directions →
The goal of this pragmatic embedded open-label, 2 x 2 factorial phase II randomized controlled trial is to evaluate strategies to improve COVID-19 booster and influenza vaccine immunogenicity in people living with immunocompromising conditions (PLIC). The main questions it aims to answer are: 1.
- Showing the first 60 of 125. Add filters or a location to narrow down.